🔎 Trials Near Me

Почетна › Колоректални карцином › Kanzas

Kliničke studije za Колоректални карцином u državi Kanzas

18 studija za Колоректални карцином traži učesnike na lokacijama u državi Kanzas.

Gradovi u državi Kanzas

Zvanični tekst studije (na engleskom)

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

  • University of Kansas, Fairway
Тражи се учесникФаза 1
Узраст од 12 до 120 · Оба пола · Ажурирано 9. 11. 2026. · NCT04222413

Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

  • Central Care Cancer Center - Garden City, Garden City
  • Central Care Cancer Center - Great Bend, Great Bend
  • Mercy Hospital Pittsburg, Pittsburg
Тражи се учесникФаза 3Здраве особе су добродошле
Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT07018869

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

  • Clinical Study Site, Westwood
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07228832

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Central Care Cancer Center - Garden City, Garden City
  • Central Care Cancer Center - Great Bend, Great Bend
  • Veteran Administration Eastern Kansas Healthcare, Leavenworth
  • и још 4
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст од 40 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT05334069

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • HaysMed, Hays
  • Lawrence Memorial Hospital, Lawrence
  • The University of Kansas Cancer Center - Olathe, Olathe
  • и још 6
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06418204

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

  • University of Kansas Cancer Center, Westwood
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06695845

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

  • Cancer Center of Kansas, Wichita
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06662786

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

  • Cancer Center of Kansas, Wichita
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06750094

Family Communications After Genetic Testing

  • Central Care Cancer Center - Garden City, Garden City
  • Central Care Cancer Center - Great Bend, Great Bend
  • Mercy Hospital Pittsburg, Pittsburg
  • и још 1
Тражи се учесникЗдраве особе су добродошле
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07143487

Lead-212 PSV359 Therapy for Patients With Solid Tumors

  • University of Kansas, Kansas City
Тражи се учесникФаза 1/2
Узраст од 18 до 90 · Оба пола · Ажурирано 28. 10. 2026. · NCT06710756

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

  • University of Kansas Clinical Research Center, Fairway
  • University of Kansas Cancer Center, Kansas City
  • University of Kansas Hospital-Westwood Cancer Center, Westwood
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT05803382

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

  • The University of Kansas Clinical Research Center, Overland Park
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 20. 10. 2026. · NCT06607458

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

  • The University of Kansas Clinical Research Center, Westwood
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 22. 9. 2026. · NCT06445062

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

  • University of Kansas Clinical Research Center, Fairway
  • University of Kansas Cancer Center, Kansas City
  • University of Kansas Hospital-Indian Creek Campus, Overland Park
  • и још 1
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 9. 9. 2026. · NCT06696768

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • The University of Kansas Cancer Center, Kansas City
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 11. 8. 2026. · NCT05592626

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

  • University of Kansas Clinical Research Center, Fairway
  • University of Kansas Cancer Center, Kansas City
  • University of Kansas Cancer Center-Overland Park, Overland Park
  • и још 2
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 31. 7. 2026. · NCT05691491

Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

  • Cancer Centers of Kansas, Wichita
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 15. 7. 2026. · NCT06937177

A Study of IBI363 in Subjects with Advanced Solid Malignancies

  • University of Kansas Medical Center (KUMC), Fairway
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 19. 12. 2024. · NCT06281678

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.